pivo schreef op 14 juli 2019 19:36:
[...]
Nog een keer dan, nu een groter deel van de tekst. Let wel, zijn twee verschillende allinea's
"
For GLPG1972, Gilead has the option to pay a $250 million fee to license the compound in the United States after the completion of the ongoing Phase 2b study in osteoarthritis. If certain secondary efficacy endpoints are met, Gilead would pay up to an additional $200 million. Following opt in,
Galapagos would be eligible to receive up to $550 million in regulatory and commercial milestones. For all other programs resulting from the collaboration, Gilead will make a $150 million opt-in payment per program and will owe no subsequent milestones. Galapagos will receive tiered royalties ranging from 20-24% on net sales of all Galapagos products licensed by Gilead as part of the agreement."